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Orthopaedic Association specializing in other fields, and 
to enlighten the general public about bone and soft tissue 
oncology. With these purposes in mind, I hope to organize 
a functional and efficient academic meeting by summariz-
ing the points for discussion.
The Annual Musculoskeletal Tumor Meeting has been 
aimed at fostering close cooperation among orthopaedists, 
pathologists, and radiologists, and specialists in these disci-
plines have made valuable contributions through exchange 
of knowledge and opinions. While acknowledging the pro-
gress that has been made in the field of bone and soft tissue 
oncology during the last few decades through this mutual 
relationship, I anticipate that the coming meeting will pro-
vide an opportunity to clarify what is needed for the future 
development of our field.
I also recognize that the coming meeting will be impor-
tant for disseminating new knowledge regarding the surgi-
cal treatment of patients with bone and soft tissue tumors, 
because this is the task that falls to orthopaedic surgeons. 
I would also like to address issues such as palliative medi-
cine, therapeutic approaches to psychosomatic medicine, 
and drug therapy for metastatic bone disease.
The last 30 years or so have also seen advances in chem-
otherapy for bone and soft tissue tumors, and a variety of 
protocols have been introduced. However, no definitive 
chemotherapy has been established for bone and soft tissue 
tumors other than osteosarcoma, and spindle cell soft tis-
sue sarcoma in particular. Meanwhile, in Europe and other 
countries, a new chemotherapeutic drug, trabectedin, was 
recently approved for the treatment of progressive soft tis-
sue sarcomas [1]. A clinical trial of trabectedin was also 
conducted in Japan, but it failed to show any clear effec-
tiveness for various bone and soft tissue tumors. There-
fore, whether trabectedin is effective in this setting needs 
to be evaluated using many more cases. On the other hand, 
The 48th Annual Musculoskeletal Tumor Meeting of the 
Japanese Orthopaedic Association (hereafter, Annual Mus-
culoskeletal Tumor Meeting) will be held July 9 and 10, 
2015, in Takamatsu, Kagawa Prefecture, Japan. Since I 
currently serve as chief of the Department  of Orthopaedic 
Surgery at Kagawa University, my duty will be to oversee 
this meeting. As the Annual Musculoskeletal Tumor Meet-
ing is one of the three major academic meetings held under 
the auspices of the Japanese Orthopaedic Association, 
managing this meeting is a great honor for both me and all 
the members of our orthopaedic surgery department here 
at Kagawa University, as well as the department’s alumni 
association. We are deeply grateful for the support of eve-
ryone involved from the Japanese Orthopaedic Association.
As I have been consistently engaged in clinical medicine 
and basic research related to bone and soft tissue tumors, I 
have regularly participated in the Annual Musculoskeletal 
Tumor Meeting. On the basis of experience obtained thus 
far, I hope that I will be able to organize a meeting that will 
prove to be productive, beneficial, and truly meaningful for 
all participants.
The purpose of the Annual Musculoskeletal Tumor 
Meeting is to introduce cutting-edge clinical medicine and 
basic research in the field of bone and soft tissue oncol-
ogy, to provide holistic therapy through palliative medicine 
and nursing care, to establish collaborative relationships 
between orthopaedics and other related medical fields, to 
provide guidelines for the diagnosis and treatment of bone 
and soft tissue tumors to the members of the Japanese 
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combination chemotherapy with gemcitabine and docetaxel 
has been reported as effective for treatment of lung cancer, 
breast carcinoma, gastric carcinoma, and ovarian cancer. 
Although combination chemotherapy using these drugs has 
been used experimentally for soft tissue sarcomas, its effec-
tiveness has not been clearly demonstrated [2]. Further-
more, second-line combination chemotherapy using these 
drugs has not been sufficiently assessed. While molecu-
lar-targeted drugs were thoroughly discussed at the 47th 
Annual Musculoskeletal Tumor Meeting in terms of basic 
research and clinical applications, pazopanib hydrochloride 
has only been widely applied since 2012 [3]. Therefore, it 
will still take several years before a sufficient number of 
patients have been treated with this drug and its mid-term 
clinical and side effects can be assessed. In the coming 
meeting, the mid-term clinical results obtained with these 
new chemotherapeutic and molecular-targeted drugs will 
be presented, and this should allow us to predict the extent 
to which these drugs will lead to improved treatment.
Denosumab, a receptor activator of the nuclear factor 
kappa-B ligand (RANKL) inhibitor, has been approved 
in Japan since 2014 for treatment of giant cell tumors of 
bone [4]. Classified as a borderline group, giant cell tumor 
of bone is one type of neoplasm that is sometimes difficult 
to control clinically. I am keenly interested in whether the 
new molecular-targeted drugs will make a significant con-
tribution to the treatment of these tumors. At the author’s 
institution, cementation for giant cell tumors of bone was 
abandoned in 2014, and the treatment now involves a com-
bination of thorough curettage and postoperative repeated 
administration of denosumab.
Meanwhile, introduction of a number of surgical tech-
nologies into the field of orthopaedics has been slow. For 
example, robotic surgery using the da Vinci Surgical Sys-
tem has been applied experimentally to head and neck 
surgery and to various types of thoracic and abdominal 
surgery, such as that for prostatic cancer [5]. However, in 
the field of orthopaedics, the prospects for introduction of 
the da Vinci Surgical System appear slim. I hope that the 
coming meeting will provide an opportunity for consider-
ing the possibility of applying the da Vinci Surgical System 
to surgery for bone and soft tissue tumors. Up to now, we 
have treated a considerable number of cases using heavy 
ion radiotherapy. The effectiveness of this technology for 
patients with inoperable bone and soft tissue tumors, as 
well as the measures taken to avoid the complications that 
it can cause, has been extensively discussed at this aca-
demic meeting in the past. However, in comparison to other 
fields, intensity-modulated radiation therapy (IMRT) has 
been used less frequently for the treatment of malignant 
tumors in the limbs and spine [6]. Unlike heavy ion radio-
therapy, however, IMRT is a comparatively simple proce-
dure to perform. I would therefore like to address the IMRT 
as an item for discussion at the coming meeting as a poten-
tial new application in the field of orthopaedics.
Reconstruction using a mega-prosthesis after treatment 
for malignant bone tumors and reconstruction using recy-
cled bone have been widely and thoroughly compared in a 
series of discussions at the Annual Musculoskeletal Tumor 
Meetings. These methods, including some older classi-
cal approaches, have been attempted over a period span-
ning some 30 years. By concentrating on long-term clini-
cal results over periods of 20 years or more, I would like 
to include these reconstruction methods, along with their 
associated complications and measures for dealing with 
them, as a discussion theme at the meeting.
Analysis of fusion genes has led to significant change in 
the classification of bone and soft tissue sarcomas, facilitat-
ing dramatic progress in their pathological diagnosis over 
the last 10 years [7]. I am interested in whether the classi-
fication of malignant tumors according to gene mutation is 
consistent with conventional diagnosis made on the basis of 
surgical pathology, and if this is not the case, in clarifying 
the types of gaps that exist between the two. Another mat-
ter of interest is clarifying the clinical course of each group 
of diseases diagnosed using gene analysis, and whether the 
progress corresponds to that of the counterpart entity diag-
nosed by conventional surgical pathology.
Although our field offers little chance for discoveries as 
dramatic as, for example, induced pluripotent stem cells 
(iPS cells), I hope that presenters at the coming meeting 
will emphasize the progress they have made and how they 
have added to conventional knowledge.
My earnest hope is that academics at universities nation-
wide and medical doctors specializing in bone and soft tis-
sue tumors will show their support and cooperation with us 
here at the Department of Orthopaedic Surgery at Kagawa 
University, in order to make the coming meeting productive 
for all participants. I will also make every effort to achieve 
this aim, along with all of our departmental members and 
those of the alumni association. I am looking forward to 
meeting you all in Takamatsu in July 2015.
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